Duchenne (DMD) and Becker (DMB) muscular dystrophies are progressive neuromuscular disorders caused by pathogenic variants in the DMD gene, which reduce or prevent the production of dystrophin. They are inherited in an X-linked manner and mainly affect males, with progressive muscle weakness and frequent cardiac and respiratory involvement.
Duchenne and Becker muscular dystrophies
The DMD gene, located at Xp21, is one of the largest genes in the human genome and encodes dystrophin, an essential structural protein for muscle fiber stability. Dystrophin connects the internal cytoskeleton to the membrane dystrophin-glycoprotein complex, protecting the muscle from repeated mechanical damage during contraction.
When pathogenic variants exist in DMD, the amount or quality of dystrophin is altered. Variants that cause a frameshift usually prevent the production of functional dystrophin and cause the most severe form, Duchenne muscular dystrophy. Variants that preserve the reading frame usually allow for a shorter, but partially functional, dystrophin and are associated with Becker muscular dystrophy. Inheritance is X-linked: hemizygous males are usually affected, and carrier females may remain asymptomatic or present with weakness, hyperCKemia, or cardiomyopathy. DMD is the most frequent muscular dystrophy in childhood, with an approximate incidence of 1 in every 3,500-5,000 live male births.
Symptoms
DMD usually begins before age 5, with motor delay, frequent falls, difficulty running, climbing stairs, or rising from the floor (Gowers' sign), abnormal gait, and calf pseudohypertrophy. Loss of ambulation typically occurs around age 12 if the natural course is not modified. BMD has a later onset, from adolescence to adulthood, and a slower progression. In both forms, contractures, scoliosis, respiratory insufficiency, and dilated cardiomyopathy can appear; in DMD, cognitive or neurodevelopmental difficulties are also relatively frequent.
Disease management
Management is multidisciplinary and aims to delay progression, maintain mobility, and prevent cardiac, respiratory, orthopedic, and nutritional complications. It includes physical therapy, adapted exercise, vaccination, respiratory support when necessary, and periodic cardiological follow-up. In DMD, corticosteroids (prednisone, prednisolone, or deflazacort) help preserve strength and motor function. Depending on the variant, targeted therapies such as exon skipping, ataluren in countries where it is authorized, or gene therapy in selected patients may be considered, always under strict criteria of indication, safety, and local availability.
Genes analyzed
Bibliography
Connuck DM, Sleeper LA, Colan SD, et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2008 Jun;155(6):998-1005.
Viggiano E, Ergoli M, Picillo E, et al. Determining the role of skewed X-chromosome inactivation in developing muscle symptoms in carriers of Duchenne muscular dystrophy. Hum Genet. 2016 Jul;135(7):685-98.
Datta N, Ghosh PS. Update on Muscular Dystrophies with Focus on Novel Treatments and Biomarkers. Curr Neurol Neurosci Rep. 2020 May 14;20(6):14.
Banihani R, Smile S, Yoon G, et al. Cognitive and Neurobehavioral Profile in Boys With Duchenne Muscular Dystrophy. J Child Neurol. 2015 Oct;30(11):1472-82.
American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics. 2005 Dec;116(6):1569-73.
